Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study

 Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) in 1L RCC Based in P-III CheckMate-214 study

Shots:

  • CHMP recommendation is based on the results of P-III CheckMate-214 study assessing Opdivo 3 mg/kg (q3w @four doses, q2w) + Yervoy 1 mg/kg vs sunitinib (50 mg qd @four weeks) in ~900 patients with 1L intermediate- and poor-risk advanced renal cell carcinoma (RCC)
  • P-III CheckMate-214 study results: increase in OS; 37% reduction in death of patients; DRR (41.6% vs 26.5%); no new safety signals observed
  • Opdivo is a PD-1 immune checkpoint inhibitor involved in fighting against cancer cells and is approved in >65 countries including the US, EU, Japan, China

Click here to read full press release/ article | Ref: Bristol-Myers Squibb | Image: New Drug Approvals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post